文献速递儿童心血管与肾脏

血清可溶性尿激酶受体水平与儿童肾脏疾病进展的关联

Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.
PubMed 文献 · JAMA Pediatr · 2017-11-06

该研究对ESCAPE试验和4C研究两个儿童慢性肾脏病队列进行事后分析,共纳入898名患儿,测量基线血清suPAR水平并纵向监测eGFR。结果发现suPAR水平最高四分位组的5年肾脏无事件生存率显著低于最低四分位组(35.9% vs 64.5%,P < .001),在基线eGFR大于40的患儿中,对数转换suPAR水平较高与CKD进展风险增加独立相关(HR 5.12,95%CI 1.56-16.7,P = .007)。

要点

  • 高suPAR水平与儿童CKD进展风险增加相关,5年肾脏无事件生存率最低四分位组为64.5%,最高四分位组为35.9%。
  • 在基线eGFR大于40 mL/min/1.73 m2的患儿中,对数转换suPAR水平较高与CKD进展风险独立相关(HR 5.12)。
  • 多变量分析显示肾小球疾病、年龄、血压、蛋白尿和较低基线eGFR也与CKD进展风险相关。

核心结论

  • 高血清suPAR水平的儿童CKD患者更易出现肾脏疾病进展。

研究设计与样本

  • 对ESCAPE试验(1999-2007)和4C研究(2010-2016)两个前瞻性儿童CKD队列进行事后分析。
  • 共纳入898名患儿,来自13个欧洲国家的30家和55家三级医院,中位随访3.1年,最长7.9年。
  • 基线测量血清suPAR水平,ESCAPE试验每2个月、4C研究每6个月测量eGFR。

主要发现

  • 5年肾脏无事件生存率在suPAR最低四分位组为64.5%(95%CI 57.4-71.7),最高四分位组为35.9%(95%CI 28.7-43.0),P < .001。
  • 多变量分析中,肾小球疾病、年龄、血压、蛋白尿和较低基线eGFR与终点事件风险增高相关。
  • 基线eGFR大于40 mL/min/1.73 m2的患儿中,对数转换suPAR水平较高与CKD进展风险独立相关(HR 5.12,95%CI 1.56-16.7,P = .007)。

关键数值与推荐

  • 主要终点为肾脏生存,定义为持续至少1个月的50% GFR丢失、开始肾脏替代治疗或eGFR小于10 mL/min/1.73 m2的复合终点。
  • 入选患儿基线平均(SD)年龄11.9(3.5)岁,平均eGFR 34(16)mL/min/1.73 m2,男性560例(62.4%)。
  • 肾脏诊断包括先天性肾脏和尿路畸形637例(70.9%)、肾小管间质性肾病92例(10.2%)、肾小球疾病69例(7.7%)、缺血后CKD 42例(4.7%)和其他CKD 58例(6.5%)。

临床怎么用

  • 血清suPAR水平可能有助于识别儿童CKD进展高风险患者,尤其是在基线eGFR大于40 mL/min/1.73 m2的患儿中。
  • 需进一步研究确定suPAR水平能否用于临床识别未来CKD风险的儿童。

局限性

  • 本研究为事后分析,结果需在前瞻性研究中验证。
  • 研究未报告suPAR检测的标准阈值或临床可操作的截断值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Conventional methods to diagnose and monitor chronic kidney disease (CKD) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate (eGFR) and assessment of proteinuria in spot or timed urine samples, are of limited value in identifying patients at risk of progressive kidney function loss. Serum soluble urokinase receptor (suPAR) levels strongly predict incident CKD stage 3 in adults. OBJECTIVE: To determine whether elevated suPAR levels are associated with renal disease progression in children with CKD. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of 2 prospectively followed up pediatric CKD cohorts, ie, the ESCAPE Trial (1999-2007) and the 4C Study (2010-2016), with serum suPAR level measured at enrollment and longitudinal eGFR measured prospectively. In the 2 trials, a total of 898 children were observed at 30 (ESCAPE Trial; n = 256) and 55 (4C Study; n = 642) tertiary care hospitals in 13 European countries. Renal diagnoses included congenital anomalies of the kidneys and urinary tract (n = 637 [70.9%]), tubulointerstitial nephropathies (n = 92 [10.2%]), glomerulopathies (n = 69 [7.7%]), postischemic CKD (n = 42 [4.7%]), and other CKD (n = 58 [6.5%]). Total follow-up duration was up to 7.9 years, and median follow-up was 3.1 years. Analyses were conducted from October 2016 to December 2016. EXPOSURES: Serum suPAR level was measured at enrollment, and eGFR was measured every 2 months in the ESCAPE Trial and every 6 months in the 4C Study. The primary end point of CKD progression was a composite of 50% eGFR loss, eGFR less than 10 mL/min/1.73 m2, or initiation of renal replacement therapy. MAIN OUTCOMES AND MEASURES: The primary end point in this study was renal survival, defined as a composite of 50% loss of GFR that persisted for at least 1 month, the start of renal replacement therapy, or an eGFR less than 10 mL/min/1.73 m2. RESULTS: Of the 898 included children, 560 (62.4%) were male, and the mean (SD) patient age at enrollment was 11.9 (3.5) years. The mean (SD) eGFR was 34 (16) mL/min/1.73 m2. The 5-year end point-free renal survival was 64.5% (95% CI, 57.4-71.7) in children with suPAR levels in the lowest quartile compared with 35.9% (95% CI, 28.7-43.0) in those in the highest quartile (P < .001). By multivariable analysis, the risk of attaining the end point was higher in children with glomerulopathies and increased with age, blood pressure, proteinuria, and lower eGFR at baseline. In patients with baseline eGFR greater than 40 mL/min/1.73 m2, higher log-transformed suPAR levels were associated with a higher risk of CKD progression after adjustment for traditional risk factors (hazard ratio, 5.12; 95% CI, 1.56-16.7; P = .007). CONCLUSIONS AND RELEVANCE: Patients with high suPAR levels were more likely to have progression of their kidney disease. Further studies should determine whether suPAR levels can identify children at risk for future CKD.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Schaefer F, Trachtman H, Wühl E, et al. Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. JAMA Pediatr. 2017. PMID: 28873129. doi:10.1001/jamapediatrics.2017.2914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。